CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a national stage application filed under 35 U.S.C. § 371 of International Patent Application No. PCT/KR2018/015865, filed Dec. 13, 2018, which claims the benefit of KR 10-2018-0066226 filed Jun. 8, 2018.

INCORPORATION OF MATERIAL OF ASCII TEXT SEQUENCE LISTING BY REFERENCE

The sequence listing submitted herewith as a text file named “MSU-1008US_Substitute Sequence Listing” created on Feb. 5, 2021, which is 39,000 bytes in size, is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

The present invention relates to a vaccine composition comprisingStaphylococcus aureusattenuated enterotoxin protein and cytotoxic protein, and more particularly toStaphylococcus aureusenterotoxin protein,Staphylococcus aureuscytotoxin protein, a vaccine composition for preventing bovine mastitis, comprising theStaphylococcus aureusenterotoxin protein andStaphylococcus aureuscytotoxin protein and a method for preventing bovine mastitis comprising administering the vaccine composition to a bovine.

BACKGROUND

Bovine mastitis directly affects milk quality and milk production so that it is a disease which the most economically damages to the dairy industry.Staphylococcus aureusis the most important etiologic agent among the causative viruses of mastitis. It is difficult to treat with antibiotics due to multiple resistance. After treatment, the prognosis is poor. Therefore, cattle infected with mastitis byStaphylococcus aureusare usually recommended to be culled. Accordingly, the prevention through vaccination is the most effective method for the management ofStaphylococcus aureusmastitis. However, the vaccine currently being developed or developed has been developed on the basis of proteins or capsules present inStaphylococcus aureusstrain. Hence, there are mutations in these antigens, which do not show any substantial preventive effect. In addition, they do not match with encapsulation type and pathogenic factors having a high frequency inStaphylococcus aureusin Korea so that the preventive effect is low. Mastitis caused byStaphylococcus aureusoccurs due to a result of complicated interactions between pathogenic factors. Mastitis is significantly increased due to enterotoxin and cytotoxin factors produced byStaphylococcus aureusso that defense mechanisms for these pathogenic factors are required for effective prevention and treatment of mastitis byStaphylococcus aureus.

DESCRIPTION OF DISCLOSURE

Technical Problem

Accordingly, the present inventors have studied effective prevention and treatment of mastitis due toStaphylococcus aureus. As a result, the present inventors have developed attenuated enterotoxin and cytotoxin by screening the most frequent pathogenic factors inStaphylococcus aureusisolated from bovine mastitis in Korean dairy cattle and confirmed excellent safety and protective ability against challenge test of the vaccine including the same, thereby completing the present invention.

Accordingly, there are objects of this invention to provide aStaphylococcus aureusenterotoxin protein, aStaphylococcus aureuscytotoxin protein, a recombinant vector including a gene encoding the proteins, a transformant into which the recombinant vector is inserted, a vaccine composition for preventing bovine mastitis, comprising theStaphylococcus aureusenterotoxin protein andStaphylococcus aureuscytotoxin protein and a method for preventing bovine mastitis, comprising administering the vaccine composition to a bovine.

Technical Solution

To achieve the objects, the present invention is to provide aStaphylococcus aureusenterotoxin protein comprising the amino acid sequences represented by SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10.

Further, the present invention is to provide aStaphylococcus aureuscytotoxin protein including the amino acid sequences represented by SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 23 or SEQ ID NO: 27. Further, the present invention is to provide a recombinant vector including a gene encoding the proteins. Further, the present invention is to provide a transformant into where the recombinant vector is inserted. Further, the present invention is to provide a vaccine composition for prevention of bovine mastitis, the composition comprisingStaphylococcus aureusenterotoxin proteins represented by SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6; andStaphylococcus aureuscytotoxin proteins represented by SEQ ID NO: 15, SEQ ID NO: 23 and SEQ ID NO: 27 as an antigen.

Further, the present invention is to provide a method for preventing bovine mastitis, the method comprising administering the vaccine composition for the prevention of bovine mastitis to a bovine.

Advantageous Effects

TheStaphylococcus aureusenterotoxin protein,Staphylococcus aureuscytotoxin protein according to the present invention and vaccine composition containing the proteins as an antigen can be used so that even vaccines containing several antigens rather than all kinds of antigens show the excellent effects of prevention and treatment of bovine mastitis against all kinds ofStaphylococcus aureusenterotoxin and cytotoxin having high incidence in Korea, thereby being more economically used for industrial purposes. Further, the vaccine composition for prevention of bovine mastitis, comprising theStaphylococcus aureusenterotoxin protein andStaphylococcus aureuscytotoxin protein according to the present invention has an excellent safety and bovine mastitis prevention and treatment effect even in the high CFUStaphylococcus aureuschallenge test so that the composition can be variously utilized inStaphylococcus aureusvaccine and prevention related fields in future.

